Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT00004923
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of docetaxel and irinotecan in treating patients who have advanced solid tumors.

Key Dates

Start date
Apr 30, 1999
Status verified
Aug 2009
Completion
May 31, 2006

Study Design

Enrollment
47 participants (actual)
Primary purpose
TREATMENT

Locations (2)

FacilityCityStateZIPSite coordinators
Yale Comprehensive Cancer CenterNew HavenConnecticut06520-8028-
Bennett Cancer CenterStamfordConnecticut06902-

Find similar trials in New Haven, CT

By research site
Yale Comprehensive Cancer Center· New Haven, CTBennett Cancer Center· Stamford, CT

Related Studies